Navigating the Schizophrenia Treatment Landscape: Antipsychotic Mechanisms and Evolving Options

In this episode, "Navigating the Schizophrenia Treatment Landscape: Antipsychotic Mechanisms and Evolving Options," the expert psychiatrists Dr. Christoph Correll and Dr. John Kane explore seven decades of antipsychotic development, tracing the evolution from first-generation dopamine blockers to emerging muscarinic cholinergic treatments.

Dr. Correll opens with a broad overview of the treatment landscape, explaining that antipsychotic pharmacology has historically centered on postsynaptic dopamine blockade. First-generation agents varied in potency, with low-potency drugs offering sedative and anxiolytic effects at the cost of greater weight gain, while high-potency agents such as haloperidol focused primarily on D2 blockade. Second-generation antipsychotics added serotonin 5-HT2A antagonism, reducing extrapyramidal symptoms but falling short of replicating clozapine's unique efficacy profile. He describes a third generation defined by refined partial dopamine agonism, and notes that a genuinely novel mechanism — muscarinic cholinergic modulation — has now emerged. Dr. Correll advocates for a neuroscience-based nomenclature focused on mechanism of action rather than generational labels, as many agents are used across multiple conditions beyond schizophrenia. He notes that while efficacy differences between agents are modest and overlapping, side effect profiles are far more predictable and clinically distinguishable.

Dr. Kane builds on this by reflecting on key comparative effectiveness trials, including CATIE and CUtLASS, which showed inconsistent advantages for second-generation agents. He highlights that second-generation drugs offered improved adherence through a reduced neurological side effect burden, though metabolic concerns emerged in their place. He raises an important methodological concern — that novel mechanisms are typically studied in patients with long treatment histories, rather than at illness onset — and calls for early-phase studies to better understand how treatments shape the trajectory of schizophrenia over time. Dr. Kane also flags tardive dyskinesia as an ongoing concern, noting that many younger clinicians lack training in its early identification, and closes with a call for both new mechanisms of action and stronger implementation of existing evidence.

The next episode in this series, "Choosing the Right Formulation in Schizophrenia Treatment," features the panelists discussing the key clinical factors that guide formulation selection — from oral to long-acting injectable to transdermal agents — both at treatment initiation and when considering a switch, emphasizing the importance of accurate diagnosis and early consideration of long-acting injectables for patients at risk of non-adherence.